The FDA's decision to request another phase 3 study is a major setback for the field. The treatment had garnered considerable support from patients, leaders in the field of mental health and psychedelics, and politicians from both parties.
The wave of enthusiasm around the drug's therapeutic potential has also come from research scientists at top academic centers and even the Department of Veterans Affairs. Still, the fate o
[
Collection
]
[
|
...
]